Alterity, FDA agree on phase 3 program for multiple system atrophy asset ATH434
Source: SeekingAlpha
2026-06-09 07:34:00 ET
More on Alterity Therapeutics
- Alterity Therapeutics Limited (ATHE) Discusses Phase II Data and Development Strategy for ATH434 in Multiple System Atrophy - Slideshow
- Alterity Therapeutics Limited (ATHE) Discusses Phase II Data and Development Strategy for ATH434 in Multiple System Atrophy Transcript
- Seeking Alpha’s Quant Rating on Alterity Therapeutics
- Historical earnings data for Alterity Therapeutics
- Financial information for Alterity Therapeutics
Read the full article on Seeking Alpha
For further details see:
Alterity, FDA agree on phase 3 program for multiple system atrophy asset ATH434
Alterity Therapeutics Limited
NASDAQ: ATHE
ATHE Trading
-3.23% G/L:
$4.80 Last:
43,890 Volume:
$5 Open:
ATHE Latest News
July 07, 2026 07:05:00 am
Alterity Therapeutics Receives FDA End-of-Phase 2 Meeting Minutes Confirming Registrational Pathway for ATH434 in Multiple System Atrophy
June 09, 2026 07:05:00 am
Alterity Therapeutics Achieves Alignment with U.S. FDA on Pivotal Phase 3 Program for ATH434 in Multiple System Atrophy
$54,331,623
14,397,880
N/A
9
N/A
Biotechnology & Life Sciences
Healthcare
AU
Melbourne
